A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

PHASE3TerminatedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

July 31, 2012

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

rhGAD65

Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.

DRUG

rhGAD65

Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.

DRUG

Placebo

Placebo injected subcutaneously at days 1, 30, 90 and 270.

Trial Locations (43)

10032

Naomi Berrie Diabetes Center of Columbia University, New York

11501

Winthrop University Hospital, Mineola

13210

SUNY Institute for Human Performance, Syracuse

14642

University of Rochester, Rochester

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19713

Christina Care Research institute, Newark

21201

University of Maryland Medical Center, Baltimore

23219

Virginia Commonwealth University, Richmond

30309

Atlanta Diabetes Associates, Atlanta

32207

Nemours Children's Clinic, Jacksonville

32610

University of Florida, Gainsville

33155

Miami Children's Hospital Research Institute, Miami

33606

University of South Florida, Tampa

38103

LeBonheur Children's Medical Center, Memphis

40202

University of Louisville Research Foundation, Louisville

40536

University of Kentucky College of Medicine, Lexington

44308

Children's Hospital Medical Center of Akron, Akron

48109

University of Michigan Health System, Ann Arbor

48126

Alzohaili Medical Consultants, Dearborn

52242

University of Iowa Hospitals and Clinicals, Iowa City

57701

Regional Medical Clinic - Endocrinology, Rapid City

63110

St. Louis Children's Hospital, St Louis

64108

The Children's Mercy Hospital, Kansas City

67211

Mid America Diabetes Associates, Wichita

68131

Creighton Diabetes Center, Omaha

70118

Children's Hospital, New Orleans

72202

Arkansas Children's Hospital Research Institute, Little Rock

72758

Alex Endocrine Associates, Rogers

74135

University of Oklahoma, Schustermann Center Clinic, Tulsa

76104

Cook Children's Medical Center, Fort Worth

78207

CHRISTUS Santa Rosa Children's Hospital, San Antonio

80045

Barbara Davis Center for Childhood Diabetes, Aurora

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

85724

University of Arizona, Tucson

89502

Kathryn Eckert, Reno

92123

Rady Children's Hospital, San Diego

92868

Children's Hospital Orange County, Orange

94305

Stanford University Medical Center, Stanford

98101

Benaroya Research Institute, Seattle

02111

Tufts Medical Center, Boston

01655

UMass Memorial Medical Center, Worcester

07601

Hackensack University Medical Center, Hackensack

07962

Morristown Memorial Hospital, Morristown

Sponsors
All Listed Sponsors
lead

Diamyd Therapeutics AB

INDUSTRY

NCT00751842 - A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT | Biotech Hunter | Biotech Hunter